48
New Schlenk component for experiments in inert atmospheres
Scharlau presents its innovative new Schlenk adapter, a glassware accessory for transforming reactions under inert or controlled vacuum atmospheres. It is designed to open up new options and optimise the efficiency in each experiment in a safer and more precise way, especially when working with compounds sensitive to various ambient conditions.
The new Schlenk adapter stands out for its capacity to transform a wide variety of glassware, from round-bottomed flasks to test tubes. This provides exceptional flexibility.
It provides the freedom to use the most suitable piece of glassware for each reaction, without having to purchase exclusively Schlenk glassware pieces. This versatility optimises equipment selection, offering a tailored approach to each experiment.
It not only improves efficiency, but also reduces costs by allowing the use of standard glassware already available in conventional laboratories. This eliminates the need for additional investment in specialised equipment.
This tool not only provides benefits in terms of efficiency and costs, but it also simplifies the equipment needed in the laboratory. It optimises storage space and helps maintain a more organised working environment.
More information online:
ilmt.co/PL/bV15 62330pr@reply-direct.com Expanding possibilities for diverse preclinical models
AMSBIO has broadened its array of products and services dedicated to supporting scientists in effectively diversifying their preclinical models, addressing the gender discrepancy gap prevalent in various research areas.
Historically, clinical trials predominantly involved men of European descent until 1993, resulting in limited data on treatment safety and efficacy for women and diverse populations. While attitudes in clinical trials are evolving, inclusivity in preclinical research often remains overlooked, creating crucial knowledge gaps regarding the impact of drugs and treatments on different populations even before advancing to human trials.
In a recent blog commemorating International Women’s Day, AMSBIO discusses the potential use of an envisioned intestinal organoid biobank to address accessibility challenges. The blog also highlights the gender reporting issues in COVID-19 vaccine development, where women experienced a
disproportionate number of side effects, underreported due to aggregated data.
As a global provider of human and animal biospecimens, AMSBIO contributes to increasing diversity in research. The company’s extensive biorepository houses various tissues from reliable sources, encompassing a comprehensive selection of healthy tissues and a variety of disease states from diverse genders and ethnicities. For specific research requirements, AMSBIO offers a custom tissue procurement service to provide samples tailored to the complexities of donor demographics.
Additionally, through a powerful synergy of novel organoids and proprietary lab-on-a-chip technology from partner ScreenIn3D (S3D), AMSBIO is uniquely positioned to assist preclinical researchers in cost-effectively developing high-throughput, data-rich assays.
Alex Sim, CEO of AMSBIO, emphasised: “A significant impetus for future clinical trials emerged from the US Federal Drug Administration in 2023. The new FDA 2.0 legislation introduces additional stratification in research by mandating more demographic requirements, including gender and race, for clinical trials and research programs. Both AMSBIO and ScreenIn3D can facilitate your research to translate this for societal benefit and the positioning of combination therapies.”
Read the informative new blog ‘Diversifying Preclinical Research’:
ilmt.co/PL/vzQx More information online:
ilmt.co/PL/4m81
62231pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148
